Clene to Present at the Emerging Growth Conference
Clene Inc. (Nasdaq: CLNN), a clinical-stage biopharmaceutical company focused on neurodegenerative diseases, has announced its upcoming presentation at the Emerging Growth Conference on April 17, 2025, at 12:00 p.m. EDT. The virtual presentation will include a corporate update followed by a Q&A session.
The company specializes in developing therapies for conditions including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS). Their flagship investigational treatment, CNM-Au8®, is a first-in-class therapy targeting mitochondrial function and the NAD pathway while reducing oxidative stress. The presentation will be accessible through the company's website and the conference portal, with replays available afterward through the Emerging Growth Conference YouTube Channel.
Clene Inc. (Nasdaq: CLNN), un'azienda biofarmaceutica in fase clinica focalizzata sulle malattie neurodegenerative, ha annunciato la sua prossima presentazione alla Emerging Growth Conference il 17 aprile 2025, alle 12:00 EDT. La presentazione virtuale includerà un aggiornamento aziendale seguito da una sessione di domande e risposte.
L'azienda si specializza nello sviluppo di terapie per condizioni come la sclerosi laterale amiotrofica (SLA) e la sclerosi multipla (SM). Il loro trattamento sperimentale di punta, CNM-Au8®, è una terapia di prima classe che mira a migliorare la funzione mitocondriale e il percorso del NAD, riducendo lo stress ossidativo. La presentazione sarà accessibile attraverso il sito web dell'azienda e il portale della conferenza, con le riproduzioni disponibili successivamente tramite il canale YouTube della Emerging Growth Conference.
Clene Inc. (Nasdaq: CLNN), una empresa biofarmacéutica en etapa clínica centrada en enfermedades neurodegenerativas, ha anunciado su próxima presentación en la Emerging Growth Conference el 17 de abril de 2025, a las 12:00 p.m. EDT. La presentación virtual incluirá una actualización corporativa seguida de una sesión de preguntas y respuestas.
La empresa se especializa en el desarrollo de terapias para condiciones como esclerosis lateral amiotrófica (ELA) y esclerosis múltiple (EM). Su tratamiento experimental insignia, CNM-Au8®, es una terapia de primera clase que se dirige a la función mitocondrial y la vía del NAD, al tiempo que reduce el estrés oxidativo. La presentación será accesible a través del sitio web de la empresa y el portal de la conferencia, con repeticiones disponibles posteriormente a través del canal de YouTube de la Emerging Growth Conference.
클렌 인크. (Nasdaq: CLNN), 신경퇴행성 질환에 초점을 맞춘 임상 단계의 생물 제약 회사가 2025년 4월 17일, 오후 12시 EDT에 Emerging Growth Conference에서 발표할 예정이라고 발표했습니다. 가상 발표는 기업 업데이트와 Q&A 세션으로 구성됩니다.
회사는 근위축성 측삭 경화증 (ALS) 및 다발성 경화증 (MS)과 같은 질환에 대한 치료법 개발을 전문으로 합니다. 그들의 주요 실험적 치료제인 CNM-Au8®는 미토콘드리아 기능과 NAD 경로를 타겟으로 하여 산화 스트레스를 줄이는 1세대 치료제입니다. 발표는 회사 웹사이트와 컨퍼런스 포털을 통해 접근할 수 있으며, 이후 Emerging Growth Conference 유튜브 채널을 통해 다시 볼 수 있습니다.
Clene Inc. (Nasdaq: CLNN), une entreprise biopharmaceutique en phase clinique axée sur les maladies neurodégénératives, a annoncé sa prochaine présentation lors de la Emerging Growth Conference le 17 avril 2025, à 12h00 EDT. La présentation virtuelle comprendra une mise à jour de l'entreprise suivie d'une session de questions-réponses.
L'entreprise se spécialise dans le développement de thérapies pour des conditions telles que la sclérose latérale amyotrophique (SLA) et la sclérose en plaques (SEP). Leur traitement expérimental phare, CNM-Au8®, est une thérapie de première classe ciblant la fonction mitochondriale et la voie NAD tout en réduisant le stress oxydatif. La présentation sera accessible via le site web de l'entreprise et le portail de la conférence, avec des rediffusions disponibles par la suite sur la chaîne YouTube de la Emerging Growth Conference.
Clene Inc. (Nasdaq: CLNN), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf neurodegenerative Erkrankungen konzentriert, hat seine bevorstehende Präsentation auf der Emerging Growth Conference am 17. April 2025, um 12:00 Uhr EDT angekündigt. Die virtuelle Präsentation wird ein Unternehmensupdate beinhalten, gefolgt von einer Q&A-Session.
Das Unternehmen ist auf die Entwicklung von Therapien für Erkrankungen wie amyotrophe Lateralsklerose (ALS) und Multiple Sklerose (MS) spezialisiert. Ihre führende experimentelle Behandlung, CNM-Au8®, ist eine Therapie der ersten Klasse, die die mitochondriale Funktion und den NAD-Weg anspricht und gleichzeitig oxidativen Stress reduziert. Die Präsentation wird über die Website des Unternehmens und das Konferenzportal zugänglich sein, mit Wiederholungen, die später über den YouTube-Kanal der Emerging Growth Conference verfügbar sind.
- None.
- None.
SALT LAKE CITY, April 14, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company dedicated to advancing therapies for neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that management will present at the Emerging Growth Conference.
Virtual Presentation Details
Date: April 17, 2025
Time of Presentation: 12:00 p.m. EDT
Format: Corporate update with Q&A
A webcast of the presentation will be available on the “Events” section of the Clene website. Alternatively, one can register for and view the webcast, along with accompanying slides, here: https://goto.webcasts.com/starthere.jsp?ei=1705403&tp_key=612b99c876&sti=clnn. A replay of the presentation will also be available through the conference portal and the Emerging Growth Conference YouTube Channel, http://www.YouTube.com/EmergingGrowthConference, following the event.
About the Emerging Growth Conference
The Emerging Growth Conference is an effective way for public companies to present and communicate their new products, services and other major announcements to the investment community from the convenience of their office, in a time efficient manner.
The Conference focus and coverage includes companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long term growth. Its audience includes potentially tens of thousands of Individual and Institutional investors, as well as Investment advisors and analysts.
All sessions will be conducted through video webcasts and will take place in the Eastern time zone.
About Clene
Clene Inc., (Nasdaq: CLNN) (along with its subsidiaries, “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc.), is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease, and multiple sclerosis. CNM-Au8® is an investigational first-in-class therapy that improves central nervous system cells’ survival and function via a mechanism that targets mitochondrial function and the NAD pathway while reducing oxidative stress. CNM-Au8® is a federally registered trademark of Clene Nanomedicine, Inc. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit www.clene.com or follow us on X (formerly Twitter) and LinkedIn.
Contacts:
| Media Contact Ignacio Guerrero-Ros, Ph.D., or David Schull Russo Partners, LLC Ignacio.guerrero-ros@russopartnersllc.com David.schull@russopartnersllc.com (858) 717-2310 | Investor Contact Kevin Gardner LifeSci Advisors kgardner@lifesciadvisors.com (617) 283-2856 |
FAQ
When is Clene (CLNN) presenting at the Emerging Growth Conference 2025?
What diseases does Clene's (CLNN) CNM-Au8® therapy target?
How does Clene's (CLNN) CNM-Au8® therapy work?
Where can investors watch Clene's (CLNN) Emerging Growth Conference presentation?
What type of company is Clene (CLNN)?
